FindTrial
Sign In

To study the effect of a test product in reducing dark spots on face in human beings.

A single group, 8 weeks, monocentric, study to evaluate the efficacy and in use tolerance of a test product in participants with hyperpigmented spots on face. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/05/086559
Enrollment
34
Registered
2025-05-08
Start date
Unknown
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: SOLGLO AZ Serum: Face will be washed and dabbed dry with towel. A thin layer of the test product will be applied on the affected areas of face, once daily at night before bedtime for a

Sponsors

FOVERO HEALTHCARE LLP.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Voluntary men and or women between the ages of 18 years to 60 years. 2. Having hyperpigmented spots on face (Age spots, Sun burn or tanning, Post inflammatory hyperpigmentation, Acne spots, Melasma specks or spots) . 3. Photo type III (skin burns moderately and tans gradually to light brown) to IV (skin burns minimally and always tans well to moderately brown). 4. Having apparently healthy skin on test area. 5. Willingness to discontinue the use of other cosmetic products on skin on the day of test product application. 6. Willing to avoid unusual sun exposure as far as possible for the entire study duration. 7. Accepting not to use products with the same end benefit during the entire study duration. 8. Cooperating, informed of the need and duration of the examinations, and ready to comply with protocol procedures. 9. Ready to provide consent, having been informed orally and in writing of all information concerning the study procedures and study objectives.

Exclusion criteria

Exclusion criteria: 1. Female who is pregnant (UPT) or lactating women. 2. Participants who have jobs or activities that involve intense sun exposure. 3. Participants hypersensitive to any of the components of the test product. 4. Participants on topical retinoids, or any skin lightening products. 5. Participants on any systemic medical treatment which may interfere with the performance of the study treatment (presently or in the past 1 month). 6. Participants who are undergoing any kind of procedures like lasers or peels for hyperpigmentation.

Design outcomes

Primary

MeasureTime frame
1. Clinical Evaluation of hyperpigmentation using a scale. 2. Evaluation of skin luminesence and hyperpigmentation using 3D Imaging. 3. Subjective Self-assessment questionnaire for efficacy .Timepoint: Day 30, Day 60—

Secondary

MeasureTime frame
NILTimepoint: Nil—

Countries

India

Contacts

Public ContactMs Preetha Paul

Clinical Aesthetics and Investigative Management Service Pvt. Ltd. (C.L.A.I.M.S.PVT.LTD.

preetha@claimsclinical.com66758851

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026